Gut microbiota of breast-fed infants are generally rich in bifidobacteria. Recent studies show that infant gut-associated bifidobacteria can assimilate human milk oligosaccharides (HMOs) specifically among the gut microbes. Nonetheless, little is known about how bifidobacterial-rich communities are shaped in the gut. Interestingly, HMOs assimilation ability is not related to the dominance of each species. Bifidobacterium longum susbp. longum and Bifidobacterium breve are commonly found as the dominant species in infant stools; however, they show limited HMOs assimilation ability in vitro. In contrast, avid in vitro HMOs consumers, Bifidobacterium bifidum and Bifidobacterium longum subsp. infantis, are less abundant in infant stools. In this study, we observed altruistic behaviour by B. bifidum when incubated in HMOs-containing faecal cultures. Four B. bifidum strains, all of which contained complete sets of HMO-degrading genes, commonly left HMOs degradants unconsumed during in vitro growth.
The mammalian gut contains trillions of bacteria that can significantly influence host health through the production of metabolites and/or direct contact with host cells 1 . The gut microbial composition changes over time, with the most drastic changes occurring at the onset and termination of breast-feeding 2 . Recent studies have shown that the gut microbiota present early on in life has long-lasting effects on host health 3, 4 ; therefore, it is important to understand how the gut microbiota is established during infancy. Bifidobacteria are well-known as first colonisers of human intestines, and generally account for more than 50% (in many cases, more than 70%) of the total bacterial population in the gut of breast-fed infants [5] [6] [7] . A bifidobacteria-rich gut microbiota is correlated with a decreased incidence of diarrhoea, allergy, and atopic dermatitis 8, 9 . Moreover, it has been shown that bifidobacteria SCIeNTIFIC REpORTS | (2018) 8:13958 | DOI:10.1038/s41598-018-32080-3
Sequencing Project accession number BBBT00000000). In the present study, we determined the complete genome sequences of strains JCM7004 and TMC3115 ( Fig. 2 and Tables S1 and S2). These two strains were chosen for analysis because they scavenge mucin-type glycans better than strains JCM1254 and TMC3108 26 (unpublished results). The circular chromosome of strain JCM7004 was 2,261,666 bp in length, and was predicted to contain 2,106 coding sequences (CDS), 57 tRNA genes, and 3 rRNA operons. The chromosome of strain TMC3115 comprised 2,178,894 bp, and was predicted to contain 1,876 CDS, 53 tRNA genes, and 3 rRNA operons. The average GC contents of the genomes were 62.6% and 62.8%, respectively. Among the seven available B. bifidum genome sequences, the genome of strain JCM7004 was the largest, while that of strain TMC3115 was the smallest (Table S1 ). Kyoto Encyclopaedia of Genes and Genomes (KEGG) orthology analysis assigned 932 functions to the 2,106 CDS of strain JCM7004, and 905 functions to the 1,876 CDS of strain TMC3115 ( Fig. 2 and Table S2 ). Among the annotated genes of both strains, more than 10% were predicted to be involved in Table 1 ). Sugars are depicted according to the nomenclature committee of the Consortium for Function Glycomics. LNFP I (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), 2′-FL (Fucα1-2Galβ1-4Glc), 3-FL (Galβ1-4(Fucα1-3)Glc), and LNnT (Galβ1-4GlcNAcβ1-3Galβ1-4Glc) are shown as representatives of the different sugar linkages. AfcA: 1,2-α-l-fucosidase; AfcB: 1,3-1,4-α-lfucosidase; LnbB: lacto-N-biosiadse; BbgIII: β-1,4-galactosidase; BbhI: β-N-acetylglucosaminidase; GL-BP: galacto-N-biose/lacto-N-biose I-binding protein of ABC transporter; GLNBP: galacto-N-biose/lacto-N-biose I phosphorylase. Dashed lines indicate pathways that have not been identified in B. bifidum. Degradants that accumulate in the spent media during culture in the presence of HMOs are indicated by asterisks (See Fig. 3 and Table S3 ).
SCIeNTIFIC REpORTS | (2018) 8:13958 | DOI:10.1038/s41598-018-32080-3 carbohydrate metabolism. Database for Carbohydrate-Active Enzyme Annotation analysis 29 revealed that the genomes of JCM7004 and TMC3115 contained 40 and 39 glycosidase hydrolase (GH)-family domains classified in the Carbohydrate-Active Enzyme database (http://www.cazy.org/) 30 , respectively. The abundance of GH-family domains, especially those dedicated to host glycan foraging, in the genomes of B. bifidum strains has been described previously 31 .
Conservation of HMO-degrading enzymes among B. bifidum strains. Previous studies using strain JCM1254 have revealed that six extracellular enzymes, one transporter, and one intracellular phosphorylase play pivotal roles in assimilating HMOs in this species (Fig. 1 ). 1,2-α-l-Fucosidase (AfcA) 23 , 1,3-1,4-α-l-fucosidase (AfcB) 24 , LnbB 25 , β-1,4-galactosidase III (BbgIII), β-1,3-N-acetylglucosaminidase I (BbhI) 26 , and sialidase II 32 are cell surface-anchored secretory enzymes that degrade all types of HMO structures into monosaccharides (Fuc, Gal, Glc, N-acetylglucosamine (GlcNAc), and Neu5Ac) and disaccharides (Lac and LNB) extracellularly. LNB is imported by the GNB/LNB transporter into the cells 22 , and is then phosphorolysed by GLNBP into galactose-1-phosphate and GlcNAc 33 (Fig. 1) , which enter the so-called bifido shunt glycolytic pathway 34 . Lac is either hydrolysed by BbgIII or imported by Lac permease 35 . AfcA, AfcB, LnbB, BbgIII, BbhI, the GNB/LNB transporter, and GLNBP show the highest preference for host-derived glycan structures. These seven enzymes constitute the minimum set required for complete digestion of neutral HMOs, which comprise >90% of the total HMOs 14 , by B. bifidum JCM1254 ( Fig. 1 ).
Genome analysis revealed that both JCM7004 and TMC3115 contain all of the genes for the above-mentioned minimum set of HMO-degrading enzymes ( Table 1) . Strain TMC3108 was also found to have these genes, as revealed by direct sequencing of the polymerase chain reaction (PCR) products. Amino acid sequence identity was very high (97.3-100%) among the respective seven enzymes from strains JCM1254, JCM7004, TMC3108, and TMC3115. Moreover, among the enzymes for which the structures have been solved (AfcA, AfcB, LnbB, the GNB/LNB transporter solute-binding protein (GL-BP), and GLNBP), the amino acid residues involved in substrate recognition and catalysis were completely conserved ( Fig. S3a-e ). The other five B. bifidum strains whose genome sequences have been reported (listed in Table S1) also contained genes coding for the complete set of enzymes, with amino acid sequence identities of >98.1%. One exception was the GL-BP of strain JCM1255 T , where a frameshift mutation had been introduced 22 , which may account for the limited growth of the strain in HMOs-supplemented medium 17 . The highly conserved nature of the HMO-degrading enzymes in B. bifidum at the species level is in sharp contrast to findings from other infant gut-associated bifidobacterial species. In B. longum, B. infantis, and B. breve, the presence of genes encoding the HMO-degrading enzymes is strain dependent, except for the GNB/LNB transporter and GLNBP 6, 7, 15, [19] [20] [21] (Fig. S1 ).
HMOs consumption behaviour of the four B. bifidum strains.
To verify the role of the seven HMO-degrading enzymes in B. bifidum during growth, we analysed the sugar composition and concentration in the spent media of the four strains cultured in medium supplemented with neutral HMOs. HMOs were purified from pooled milk of 14 Japanese mothers. The samples were collected at the indicated time points ( Fig. S2 ) and subjected to a normal-phase high performance liquid chromatography (HPLC) following 2-aminoanthranilic acid (2-AA)-labelling of mono-and oligosaccharides (Figs 3 and S4 and Table S3 ). The results revealed that HMO consumption behaviours were very similar among the four strains, reflecting the conserved nature of the enzymes. The HMO degradation patterns were also similar to our previous observations 22 . The degradation of LNT and 2′-fucosyllactose (2′-FL), which are the major components of HMOs, began prior to cells entering exponential phase, and the majority of these two substrates was degraded by early exponential phase, indicating the rapid action of LnbB and AfcA, respectively [23] [24] [25] 36 . As a result, transient increases in the concentrations of LNB (at least 0.3 mM, see the Methods section) and Lac (up to 1.9 mM) were observed. Gal was liberated from lacto-N-neotetraose (LNnT: Galβ1-4GlcNAcβ1-3Galβ1-4Glc) and Lac by BbgIII, and accumulated in the spent medium throughout the growth period. Glc concentrations remained low during growth except for strain JCM7004. The impaired Glc consumption ability of JCM7004 might account for lower cell biomass formation of the strain than the other three strains during growth ( Fig. S2 ). GlcNAc was not detected throughout the growth period. 
B. bifidum-mediated cross-feeding of HMOs degradants to B. longum.
To examine the possibility of the symbiotic sharing of HMO degradants among bifidobacteria, we attempted to disrupt the afcA (1,2-α-l-fucosidase) or lnbB (lacto-N-biosidase) genes in the B. bifidum strains. However, all attempts were unsuccessful. Therefore, we performed simple in vitro co-culturing of B. longum 105-A and B. bifidum JCM1254 in HMOs-supplemented medium ( Fig. 4a upper panel) . Whereas wild-type (WT) strain of B. longum 105-A (LnbX + ) showed very limited growth on HMOs in mono-culture, it grew well when co-cultured with B. bifidum, suggesting cross-feeding of HMOs degradants at the inter-species level. Growth competition experiments showed that the lnbX gene is dispensable for B. longum to utilize HMOs degradants produced by B. bifidum (Fig. 4a lower panel). However, the gene was found to be indispensable for the strain when grown in LNT as a sole carbon source. The ΔlnbX derivative of B. longum 105-A was incapable of assimilating LNT in mono-culture, while it grew well in the presence of WT B. longum 105-A (LnbX + ) ( Fig. 4b ), implicating that WT LnbX + cells can feed ΔlnbX cells with LNT degradants (Lac and/or LNB). Such intra-species level cross-feeding may also occur in gut microbial community. stool samples collected from one infant, two young children, and two adults (Table S4 ). The initial abundance of 16S rRNA gene copies attributed to members of the genus Bifidobacterium in stool suspensions from child A, child B, infant C, adult D, and adult E was 1.0 × 10 8 , 4.7 × 10 8 , 3.1 × 10 4 , 1.1 × 10 9 , and 3.9 × 10 9 copies/mL, respectively, at 0 h (Fig. 5a ). The 16S rRNA gene copies specifically attributed to B. bifidum was below the detection limit of our quantitative PCR (qPCR) system (<4.0 × 10 4 copies/mL) in all samples except for adult D sample (Fig. S5 ). The stool suspensions were incubated for 24 h in medium supplemented with 1% HMOs, either in the presence or absence of each of the four B. bifidum strains. Addition of B. bifidum considerably stimulated the growth of other Bifidobacterium species in all cases, except for adult E samples and for TMC3115-added child B sample. Statistical significances were detected in 10 out of 15 cases for which the stimulatory effects of B. bifidum were observed (p < 0.05, Dunnett's test) ( Fig. 5a ). In stool cultures from child A, the observed growth promotive effect was 60-, 130-, 290-, and 990-fold for strains JCM1254, JCM7004, TMC3108, and TMC3115, respectively, compared with the control culture without supplementation of B. bifidum. For stool cultures from child B, we observed 2.5-, 1.6-, and 1.7-fold increases in the number of 16S rRNA copies attributed to other bifidobacterial species in the presence of strains JCM1254, JCM7004, and TMC3108, respectively, compared with the control.
In the case of stool sample obtained from infant C, the growth of other bifidobacterial species was stimulated by 1,700-to 10,000-fold by adding B. bifidum strains, while 1.4-to 14-fold stimulation was observed for the sample from adult D, compared with none-added control. Consequently, the prevalence of bifidobacterial species other than B. bifidum in total bacteria was increased when B. bifidum strains were added to the faecal samples in all cases, except for the child B stool sample supplemented with TMC3115 and for the adult E samples (Fig. 5b) .
Particularly, drastic increases of the prevalence of other bifidobacterial species in total bacteria were observed in faecal cultures from the child A and infant C samples. It should be noted that although the B. bifidum 16S rRNA gene was not detected in the control cultures from stool samples from child A and infant C after 24 h, it was detected in the non-added control cultures of stool samples from child B, adult D, and adult E after 24 h incubation (1.8 × 10 6 , 3.1 × 10 9 , and 1.5 × 10 7 copies/mL, respectively) (Fig. S5a) . The results indicate the latter three faecal samples contained B. bifidum cells endogenously when collected. The culture supernatants were also analysed by thin-layer chromatography (TLC) (Fig. S6a ). In the control cultures of stool samples from child A and infant C, the spots corresponding to 2′-FL, LNFP I, LNDFH I, and longer HMOs appeared to be undigested even after cultivation for 24 h. However, when the stool samples were co-cultivated with each of the four B. bifidum strains, these oligosaccharides were almost completely consumed. In stool sample B, a spot corresponding to LNDFH I was detected in the control culture, but disappeared when the four B. bifidum strains were added. In the supernatant of cultures of adult D and adult E samples, no obvious spots were detected in the TLC analysis both for the control and B. bifidum-added cultures after 24 h incubation. In contrast to the results obtained from HMOs-containing cultures, when the same experiments were conducted using Glc as the carbon source, the growth stimulatory effects of B. bifidum were not evident (Fig. S7a) . Addition of B. bifidum JCM1254 and TMC3108 to the stool suspensions from child A and infant C, respectively, increased the 16S rRNA gene copy numbers of other Bifidobacterium species by 5.6-and 9.3-fold; however, in the other cultures, the copy numbers were unchanged or decreased. Reflecting these results, bifidobacterial populations other than B. bifidum in total bacteria were also unchanged or decreased considerably compared with those of the control cultures that were not supplemented with B. bifidum (Fig. S7b) . Regardless of the carbon source used (HMOs or Glc), the supplemented B. bifidum strains grew well in the faecal cultures (Fig. S5) . The final pHs of the broths were neutral (6.4-7.7) when the faecal suspensions were cultured in the presence of HMOs, while they dropped to 5.1-6.1 when incubated with Glc (Table S5 ). Taken together, these results strongly suggest that HMO degradants produced by B. bifidum are used to feed not only themselves but also other bifidobacterial species, thereby increasing the prevalence of bifidobacteria in faecal cultures. The growth stimulatory effect was found to be less effective when the collected faecal sample intrinsically contains B. bifidum cells already.
Discussion
The intestinal microbial composition is influenced not only by host-microbe interactions, but also by microbe-microbe interactions in the gut. Competition between bacterial species in the gut is a well-known example of microbe-microbe interactions, and can help prevent colonization by invading pathogenic bacteria 38 . However, recent studies have revealed complex microbe-microbe interactions involving cross-feeding among different microbes. Cross-feeding is thought to occur both bidirectionally and unidirectionally. Bidirectional feeding is observed between Bacteroides ovatus and Bacteroides vulgatus, which is mediated through inulin 39 , and between Akkermansia muciniphila and Eubacterium hallii, which is mediated through O-glycan degradants derived from mucin and pseudovitamin B12 40 . Unidirectional feeding is found between A. muciniphila and Anaerostipes caccae, in which acetate produced by A. muciniphila stimulates the growth of A. caccae 40 , and between Bifidobacterium adolescentis and Faecalibacterium prausnitzii, whereby acetate that is required for the growth of F. prausnitzii is provided by B. adolescentis 41 . Apparently, intra-and inter-genus feeding of degradants and metabolites among bacteria increases gut microbiota diversity, which is thought to be important for shaping a flexible, healthy gut environment 42 .
Over the last decade, several groups, including our own, have focused on elucidating the mechanism of HMOs degradation by bifidobacteria. These studies revealed that HMOs assimilation is essentially limited to infant gut-associated bifidobacterial species represented by B. infantis, B. longum, B. breve, and B. bifidum. Interestingly, although the four species belong to the same genus, they have evolved different strategies to degrade HMOs (i.e., the extracellular glycosidase-dependent one adopted by B. bifidum and LnbX-positive B. longum, or the transporter-dependent one observed in B. breve, B. infantis, and LnbX-negative B. longum), resulting in varied HMO consumption behaviours. LoCascio et al. found that B. infantis strains that grow in the presence of HMOs share a 40-kb gene cluster encoding ABC transporters and intracellular exoglycosidases that act on HMOs, allowing B. infantis to consume most of HMOs 43 . B. bifidum is also an avid consumer of HMOs, and in the present study, we demonstrated that this phenotype can be attributed to the conserved presence of HMOs-degrading enzymes in this species . In contrast to B. infantis and B. bifidum, B. breve and B. longum are fastidious about HMOs consumption. The two species commonly consume LNT, but assimilation of the other HMOs is variable and strain-dependent 19, 20 . Some B. breve strains can degrade LNnT, 2′-FL, and/or 3-FL 6, 18 , and some B. longum strains can consume 2′-FL and LNFP I in addition to LNT. Although 2′-FL, 3-FL, and LNFP I constitute major HMOs (Table S3) , breast-fed infant B. breve and B. longum faecal isolates frequently lack the genes required to assimilate these HMO molecules 19 . Consequently, at the species level, the ability of B. breve and B. longum strains to assimilate HMOs is limited compared with B. infantis and B. bifidum. Nonetheless, interestingly, infant gut microbiota is frequently dominated by B. breve and/or B. longum 6, 15 . Thus, the formation of a bifidobacteria-rich microbiota in the breast-fed infant gut is not simply explained by HMOs assimilation phenotypes.
Our previous findings showed that B. bifidum JCM1254 leaves some HMOs degradants unconsumed during growth, while a report by Tannock et al. described the positive relationship between occurrence of B. bifidum and the abundance of Bifidobacterium at the genus level in the faeces of breast-fed infants 5 . These findings led us to consider the possibility of B. bifidum-mediated cross-feeding of HMOs degradants to other bifidobacterial species. First, we showed that all four B. bifidum strains examined release HMOs degradants during cultivation, and then demonstrated that inter-and intra-species cross-feeding of HMOs degradants among bifidobacteria. B. longum proliferated in HMOs-containing broth only when co-cultured with B. bifidum (Fig. 4) . Whereas lacto-N-biosidase-deficient B. longum strain did not assimilate LNT, it grew well on LNT when co-cultivated with its parental WT B. longum strain. Given the results, we extended our hypothesis to more complex ecosystem, e.g. faecal samples. Our current findings show that, when added to faecal cultures, the four B. bifidum strains considerably stimulate the growth of other bifidobacterial species (except for the adult E samples). In addition, HMOs that remained unconsumed in the control cultures of stool samples from child A, child B, and infant C disappeared when the faecal samples were co-cultivated with B. bifidum. Growth promotive effects were evident in HMOs-containing cultures, but not apparently observed in Glc-containing culture (Fig. 5 vs. Fig. S7 ). It is interesting to note that B. bifidum was detected in the non-added control cultures of faecal samples B, D, and E after 24 h of cultivation in the presence of HMOs, but was not detected in the control cultures of faecal samples A and C. Considering that the growth-promoting effects of B. bifidum were more evident in faecal samples A and C than in faecal samples B, D, and E, endogenously present B. bifidum in the collected stool samples might assist the growth of other bifidobacterial species in the non-added control cultures of faecal samples B, D, and E, which slightly (for B and D) or completely (for E) masked the stimulatory effects of exogenously supplemented B. bifidum strains (Figs 5 and S5 ). It should be mentioned, in terms of intervention, that bifidobacterial population and occupancy was greatly increased in HMOs-supplemented stool sample obtained from infant C, who was a caesarean-delivered preweaning infant.
Finally, we examined the effect of α-fucosidase inhibitor deoxyfuconojirimycin (DFJ) 37 on the cross-feeding of HMOs degradants among bifidobacteria. Addition of DFJ to the HMOs-supplemented faecal cultures of child A completely abolished the growth stimulatory effects of the all B. bifidum strains (Fig. S8) . The results could be caused by DFJ-mediated inhibition of hydrolysis of fucosylated HMOs, because the TLC analysis of the spent media revealed that 2′-FL, LNFP I, and LNDFH I remain unconsumed after 24 h incubation (Fig. S6b) . Thus, extracellular glycosidase-dependent HMO-consumers may at least be involved in unidirectional cross-feeding of other microbes. These results strongly suggest altruistic behaviour by B. bifidum (and probably LnbX + -B. longum) to establish a bifidobacteria-rich microbiota in the gut of breast-fed infants, although we cannot rule out the possibility that an unidentified metabolite produced from HMOs by B. bifidum stimulates the growth of other bifidobacterial species. The altruistic behaviour of B. bifidum may also occur in adult intestines. Egan et al. described possible cross-feeding of mucin degradants produced by B. bifidum to B. breve 44, 45 . Mucin is a highly glycosylated protein that is abundantly expressed in the human large intestine, and B. bifidum possesses cell wall-anchored secretory glycosidases to degrade the sugar chains 16, 46, 47 . Interestingly, most of the mucin-degrading glycosidases are commonly used for degradation of HMOs 16 , reflecting the similarities in the glycoside linkages between mucin glycans and HMOs.
In summary, our findings reveal conservation in HMO-degrading enzymes and HMO consumption behaviour among B. bifidum strains, and suggest that B. bifidum could serve as a key player to establish a bifidobacteria-rich microbiota in the breast-fed infant gut, by providing HMOs degradants. These results enhance our understanding of how the bifidus flora is formed during infancy, and provide insight into how we could fortify prebiotic and probiotic foods, including infant formula, to enhance the bifidobacterial population in the infant gut.
Methods
Chemicals. 2′-FL, 3-FL, LNnT, LNFP I, and LNDFH II were purchased from Dextra Laboratory (Reading, UK). LDFT and LNT were obtained from IsoSep (Tullinge, Sweden), or as gifts from Glycom A/S (Denmark). LNFP II and LDFH I were purchased from Carbosynth (Berkshire, UK). DFJ was obtained from Sigma-Aldrich (MO, USA). Isomaltopentaose was from Seikagaku Kogyo (Tokyo, Japan), while LNB was synthesized as previously described 48 . 2-AA and sodium cyanoborohydride were obtained from Nacalai tesque (Kyoto, Japan). All other reagents were of analytical grade.
Bacterial strains and culture conditions. Bacteria used in this study included B. bifidum strains JCM1254, JCM7004, TMC3108, and TMC3115, along with B. longum 105-A and its lacto-N-biosidase gene disruptant ΔlnbX 7,49 . Strains JCM1254 and JCM7004 were obtained from the Japan Collection of Microorganisms (JCM; RIKEN Bioresource Center, Japan), while strains TMC3108 and TMC3115 were isolated previously from infant stools 47, 50 . B. longum 105-A was obtained from Dr. Yasunobu Kano 49 . All strains were routinely grown in GAM broth (Nissui Pharmaceutical, Tokyo, Japan) under anaerobic conditions using the AnaeroPack system (Mitsubishi Gas Chemical Co., Tokyo, Japan). When examining growth in medium supplemented with HMOs, basal medium (0.2% yeast extract, 1.0% peptone, 0.5% sodium acetate, 0.2% diammonium citrate, 0.02% magnesium sulphate, 0.2% dipotassium hydrogen phosphate, and 0.1% cysteine hydrochloride) was used. The medium was supplemented with 4% reducing reagent (2% cysteine hydrochloride and 11% sodium carbonate) and 1% SCIeNTIFIC REpORTS | (2018) 8:13958 | DOI:10.1038/s41598-018-32080-3 sugar prior to inoculation. Three separate broths were inoculated with overnight culture of each strain and incubated anaerobically at 37 °C. Growth was monitored by measuring the OD 600 , or by determining CFU at the indicated time points. The data are expressed as means ± standard deviation (SD).
Whole genome sequencing. Genomic DNA was extracted from B. bifidum strains JCM7004 and TMC3115 using a Wizard Genomic DNA Purification kit (Promega, WI), and was sequenced with ~540-fold and ~260-fold coverage, respectively, using a PacBio RS II sequencer (Pacific Biosciences, CA). The sequences were assembled using SMRT Analysis software v2.3.0. Additional sequencing was carried out using a HiSeq. 2500 system (Illumina, San Diego, CA) to fill the gaps. Sequencing and analysis were performed by the Dragon Genomic Center at TaKaRa Bio (Shiga, Japan), Eurofins Genomics (Tokyo, Japan), and Beijing Genomics Institute (Guangdong, China). Glimmer3 51 was used to predict open reading frames, and gene annotations were assigned by KAAS 52 , based on the KEGG 53 database.
Direct sequencing of PCR products. The genes coding for the HMO-degrading enzymes of B. bifidum TMC3108 were amplified in high-fidelity PCR using PrimeSTAR Max (TaKaRa Bio) and genomic DNA as a template. The primers used for amplification are listed in Table S6 . The amplified fragments were purified, and then directly sequenced using a primer walking method.
Preparation of HMOs from human milk. HMOs were purified from human milk as described previously 22 . Milk samples were collected at Nagao Midwife Clinics (Kyoto, Japan) from 14 healthy Japanese mothers who had not taken any antibiotics for 1 month prior to collection. Informed consent was obtained from all mothers.
Sugar concentration analysis.
Mono-and oligosaccharides in the culture supernatants were quantified by HPLC analysis following fluorescence-labelling of sugars. Aliquots (50 μL) of the culture incubated in the presence of HMOs were collected at the indicated time points, clarified by centrifugation, and stored at −20 °C until use. For the HPLC analysis, the supernatants were thawed and immediately mixed with 30 μL of water and 20 μL of 0.1% isomaltopentaose (internal standard). The sugars in the samples were then labelled with 2-AA, as described previously 22 . It should be noted that LNB is rapidly decomposed during heat treatment, and thus the concentrations shown in this paper correspond to less than half of its original concentrations in the medium. HPLC was carried out using a Waters e2695 separation module (Waters, Milford, MA) equipped with a TSKgel Amide-80 HR column (4.6 × 250 mm, ϕ = 5 μm) (Tosoh, Tokyo, Japan) at 65 °C. The column was equilibrated with 85% solvent A (acetonitrile)/15% solvent B (100 mM ammonium formate buffer, pH 4.3). The elution was performed using a linear increase of solvent B (from 15% to 40%) over 90 min at a flow rate of 1 mL/min. The labelled sugars were detected at excitation and emission wavelengths of 330 and 420 nm, respectively, using a Waters 2475 Fluorescence Detector. The sugar concentrations were determined based on the standard curves generated using similarly labelled standard sugars. The data were normalised using the internal standard and expressed as means ± SD of the labelled sugars obtained from three separate cultures. -culture of B. longum with B. bifidum. WT strain of B. longum 105-A with a plasmid carrying the chloramphenicol resistance gene (pBFS38) 54 was cultured in basal medium supplemented with 1% HMOs as a carbon source in the presence and absence of B. bifidum JCM1254. During incubation, aliquots were collected, serially diluted, and spread on GAM agar plates supplemented with and without 2.5 μg/mL of chloramphenicol. Colonies appearing on the antibiotic-containing plates were attributed to B. longum cells, while those formed on antibiotic-free plates were assumed to represent the sum of B. longum and B. bifidum cells. When the ΔlnbX derivative of B. longum 105-A was competed against its parental WT strain (with pBFO2 carrying the spectinomycin resistance gene 55 ) for the growth on HMOs in the presence of B. bifidum, pBFS38 was introduced into ΔlnbX strain to distinguish between them. WT and ΔlnbX derivative were also cultured separately or in combination in basal medium supplemented with 1% LNT as a carbon source. Different antibiotic resistance genes were introduced into the two strains by plasmids (pBFO2 or pBFS38) to distinguish between them. During incubation, aliquots were collected, serially diluted, and spread on GAM agar plates containing the respective antibiotics to determine the CFUs of each strain. Spectinomycin and chloramphenicol were used at the final concentrations of 30 μg/mL and 2.5 μg/mL, respectively. Table S4 . The samples were immediately stored under anaerobic conditions, and then transferred to the laboratory. The stools were suspended in 20% glycerol in an anaerobic chamber (InvivO 2 400; Baker Ruskinn, Bridgend, UK), and then frozen at −80 °C until use. Thawed stool samples A−E were used to inoculate 1 mL of basal medium containing 1% HMOs or Glc as a carbon source. At 0 h post-inoculation, the faecal suspensions from child A, child B, infant C, adult D, and adult E samples contained 16S rRNA gene copies attributed to total bacteria at the concentrations of 7.9 × 10 8 , 3.2 × 10 9 , 4.4 × 10 9 , 1.7 × 10 10 , and 1.7 × 10 10 copies/mL, respectively. When needed, DFJ was added to the culture at a final concentration of 500 μM. Following further incubation for 24 h, the abundance of B. bifidum (species level) and Bifidobacterium (genus level) in each sample was examined by qPCR analysis of the 16S rRNA gene. In brief, each culture was centrifuged, and the precipitate was resuspended in 1 mL of TE buffer (10 mM Tris-HCl containing 1 mM EDTA, pH 8.0). The suspension was transferred to a 2-mL plastic tube containing a stainless steel bead (ϕ = 5.0 mm) and zirconia beads (ϕ = 0.1 mm, equivalent to 100 μL volume) before being shaken vigorously at 1,500 rpm for 10 min using a Shake Master Neo (Bio Medical Science, Tokyo, Japan). Total DNA was SCIeNTIFIC REpORTS | (2018) 8:13958 | DOI:10.1038/s41598-018-32080-3 then extracted using a standard phenol-chloroform method from the lysate, and examined using the SYBR Green system (TaKaRa Bio). The data are means ± SD of three independent experiments. The prevalence of bifidobacteria was calculated by dividing bifidobacterial 16S rRNA gene counts (except for B. bifidum) by total bacterial 16S rRNA gene counts. The primers used are listed in Table S6 . Spent media were used for measurement of the pH values with micro pH meter (HORIBA, Kyoto, Japan) and for TLC analysis with a silica gel 60 aluminium sheet (Merck, Darmstadt, Germany). The plate was developed in a solvent system consisting of 1-buthanol:acetic acid:water (2:1:1). Sugars were visualized as described previously 56 . Graphics. The genomic structure was schematically drawn using the R package "circlize" library 57 .
In vitro co
Protein structure images were prepared using PyMOL (Schrödinger, Inc., NY). The amino acid sequences of HMO-degrading enzymes were aligned using Clustal Omega 58 , and the alignment was shown using BoxShade 3.2.1 (http://www.ch.embnet.org/software/BOX_form.html).
Statistical analysis.
Statistical analyses were performed using BellCurve version 2.00 (SSRI, Tokyo, Japan) and Excel 2013 (Microsoft) software. Dunnett's test was used to examine the statistical significance, where p values of less than 0.05 were regarded as statistically significant.
Ethical consideration. This study was reviewed and approved by the Ethics Committees of Kyoto University (R0046) and the University of Shiga Prefecture (71-3), and was conducted in accordance with the Declaration of Helsinki.
